The MeritCare Hospital Community Clinical Oncology Program, composed of MeritCare Hospital, MeritCare Medical Group, and MeritCare Roger Maris Cancer Center and affiliate organization Fergus Falls Medical Group, propose to provide state-of-the-art cancer treatment and prevention and control research to individuals through participation in National Cancer Institute approved clinical trials. The CCOP proposes to refine and expand its existing program by: 1) increasing the number of eligible patients placed on NCI approved clinical trials through affiliations with four cooperative research groups and strengthening relationships with primary care physicians through education, communication and feedback on accrual, 2) increasing the number of minorities entered on clinical trials through partnerships with primary care providers serving minorities, enhanced communication with agencies serving minorities, continuing to serve the medically underserved of the service area, and developing a continuous monitoring system for minority recruitment, 3) increasing the quality and efficiency of data management systems through increased automation, and quality monitoring systems at the components and affiliate organization, and 4) expanding cancer prevention and control participation in clinical trials through participation in large-scale prevention trials as well as other cancer control studies available through cooperative research groups and strengthening relationships and referral patterns with primary care providers in the service area.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA037417-19
Application #
6512480
Study Section
Special Emphasis Panel (ZCA1-SRRB-7 (J4))
Program Officer
Minasian, Lori M
Project Start
1983-09-30
Project End
2004-05-31
Budget Start
2002-06-01
Budget End
2003-05-31
Support Year
19
Fiscal Year
2002
Total Cost
$739,641
Indirect Cost
Name
Roger Maris Cancer Center
Department
Type
DUNS #
City
Fargo
State
ND
Country
United States
Zip Code
58103
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
Schild, Steven E; Hillman, Shauna L; Tan, Angelina D et al. (2017) Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance). J Thorac Oncol 12:697-703
Bhatia, Aarti K; Lee, Ju-Whei; Pinto, Harlan A et al. (2017) Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590). Cancer 123:4653-4662
Sio, Terence T; Atherton, Pamela J; Birckhead, Brandon J et al. (2016) Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Support Care Cancer 24:3847-55
Neal, Joel W; Dahlberg, Suzanne E; Wakelee, Heather A et al. (2016) Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Lancet Oncol 17:1661-1671
Pachman, Deirdre R; Qin, Rui; Seisler, Drew et al. (2016) Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer 24:5059-5068
Park, Haeseong; Qin, Rui; Smith, Thomas J et al. (2015) North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes. Menopause 22:627-32
Dronca, Roxana S; Allred, Jacob B; Perez, Domingo G et al. (2014) Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675. Am J Clin Oncol 37:369-76
Barton, Debra L; Thanarajasingam, Gita; Sloan, Jeff A et al. (2014) Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance). Cancer 120:3575-83
Province, M A; Goetz, M P; Brauch, H et al. (2014) CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther 95:216-27

Showing the most recent 10 out of 136 publications